B.C. Cho - Yonsei Cancer Center, Yonsei University College of Medicine

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 39 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study

M.R. García Campelo,B.C. Cho, N. Girard, S. Lu, H. Yoshioka, J-S. Lee,S-H. Lee, B. Liu, M.A.N. Sendur, B. Besse, A. Spira, E. Felip,

ESMO Open (2024)

引用0浏览0引用

147P Population-adjusted indirect comparisons of repotrectinib and entrectinib in ROS1+ locally advanced or metastatic non-small cell lung cancer (NSCLC)

J. Wolf, S. Goring, A. Lee,B.C. Cho, A. Drilon, G. Lozano-Ortega, Y. Yuan, E.E. Korol, D. Ayers, M. Crabtree, L. Huria, E. Popoff,

ESMO Open (2024)

引用0浏览0引用

12P Atezolizumab plus bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance: Final results from the randomised, non-comparative phase II ETOP ABC-lung trial

M. Frueh, R.A. Soo, A. Vervita,B.C. Cho, M. Majem,D. Rodriguez Abreu, A. Callejo Perez,M.T. Moran Bueno,M. Domine Gomez,M. Provencio Pulla, A. Addeo,J-Y. Han,

ESMO Open (2024)

引用0浏览0引用

90P Real-world (RW) post-progression outcomes and treatment (tx) patterns after first-line (1L) immuno-oncology (IO) regimens in patients (pts) with metastatic (m) NSCLC: CORRELATE

S.V. Liu, R.J.-B. Salomonsen, P.M. Forde, J. Naidoo,B.C. Cho, V. Graziano, A. Wang, M. Cooper, T. Shcherbakova, S. Peters

ESMO Open (2024)

引用0浏览0引用

60P Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC): Efficacy results by histology from the EVOKE-02 study

F. Cappuzzo, J. Patel,B.C. Cho,M. Cobo Dols, R.M. Reyes Cabanillas,D. Vicente Baz, J. Fuentes Pradera, J. Neal, E.B. Garon, S. Mekan, F. Safavi, N. Fernando,

ESMO Open (2024)

引用0浏览0引用

6MO Subcutaneous amivantamab administered every 4 weeks (Q4W) in patients with advanced solid malignancies: The phase Ib PALOMA study

N. Leighl, A.R. Minchom, K.H.H. Lee, M.G. Krebs,B.C. Cho, Y.J. Kim, M.L. Johnson, J. Sabari, B. Sanusi, A. Alhadab, N. Haddish-Berhane, D. Zemlickis,

ESMO Open (2024)

引用0浏览0引用

Lazertinib vs Gefitinib in Treatment-Naive Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis

T. Reungwetwattana,B. C. Cho, K. H. Lee, Y. K. Pang, C. H. Fong,J. H. Kang, Y. -G. Lee,C. S. Lim, P. Danchaivijitr, Y. N. Lim, Y. Lee, S. H. How,

JOURNAL OF THORACIC ONCOLOGY（2023）

引用0浏览0引用

Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis

J-Y. Shih, J. Wang, Y. Wang, J. Wang,S-H. Lee, K. Azuma, T. Takahashi,J-L. Tan,C. C. Lin, S. Ganguly, V. H. F. Lee, P-L. Chu,

ANNALS OF ONCOLOGY (2023): S1661-S1662

引用0浏览0引用

Study Design to Assess Anti-TIGIT Mab Combination with Dostarlimab vs Pembrolizumab or Dostarlimab Monotherapy in NSCLC

D. R. Spigel,B. C. Cho, M. Reck, K. Nakagawa, S. Wimalasundera, E. Parkhomenko, R. Parasrampuria, L. Parker, A. Khaled, M. Satouchi

Journal of Thoracic Oncologyno. 11 (2023): S319-S319

引用0浏览0引用

TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

M-J. Ahn,B. C. Cho, Y. Goto, K. Yoh,W-C. Su, J. Shimizu, J-S. Lee, S. Oizumi,J. C-H. Yang, H. Hayashi, H. Zebger-Gong, K. Sugiura,

ANNALS OF ONCOLOGY（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn